LONDON, UK / ACCESSWIRE / October 24, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK) ("GSK"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=GSK. The Company announced on October 20, 2017, that the US Food and Drug Administration (FDA) has granted marketing authorization to its herpes zoster vaccine, SHINGRIX, containing the proprietary immune adjuvant QS-21 Stimulon® of Agenus Inc. (NASDAQ: AGEN). For immediate access to our complimentary reports, including today's coverage, register for free now at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on GSK and AGEN. Go directly to your stock of interest and access today's free coverage at:
SHINGRIX is indicated for the prevention of herpes zoster, also known as shingles, in adults aged 50 years and older. The addition of QS-21 Stimulon® helps improve the vaccine's effectiveness by boosting the immune response in older adults who often experience age-related decline in immunity.
Why the Drug Matters
Shingles is a major public health issue in the US, impacting as many as 1 in 3 older adults over the age of 50 years. Shingles is caused by a virus called varicella zoster, which is also known as the chicken pox virus. Nearly all older adults have the varicella zoster virus dormant in their nervous system waiting to reactivate with advancing age and weakened immune systems.
QS-21 Stimulon® is an immune-potent adjuvant designed to boost the immune system by helping the body generate antibodies and T cells which guard against infections. The addition of QS-21 Stimulon® to the SHINGRIX vaccine enhances the immune response in these older adults.
The FDA approval of SHINGRIX was based on data pooled from two pivotal Phase-III clinical trials in more than 38,000 people. SHINGRIX demonstrated an efficacy rate against shingles greater than 90% independent of age, as well as a sustained efficacy over the four-year follow-up period. SHINGRIX also reduced the overall incidence of post-herpetic neuralgia (PHN), the most common and oftentimes debilitating chronic nerve pain associated with shingles. The benefit of SHINGRIX in the prevention of PHN can be attributed to the effect of the vaccine on the prevention of shingles.
The addition of QS-21 Stimulon® is being studied to determine its potential to help a diverse range of vaccines work more effectively to treat or cure difficult-to-treat diseases, like cancer. QS-21 Stimulon® is currently being used in combination with Agenus' neo-antigen vaccine, AutoSynVax™, now in a Phase-1 clinical trial in cancer. QS-21 Stimulon® is also currently being evaluated in numerous GSK vaccine development candidates for both therapeutic and prophylactic applications.
On 13 October, 2017, SHINGRIX was approved in Canada for the prevention of shingles in people aged 50 years, or older. GSK noted that the regulatory filings in the European Union, Australia, and Japan are underway. Following this approval from the FDA, and pending a recommendation from ACIP, SHINGRIX will be available in the US shortly.
About Agenus Inc.
Agenus is a clinical-stage immuno-oncology Company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA.
About GlaxoSmithKline PLC
GSK is one of the world's leading research-based pharmaceutical and healthcare Companies, committed to improving the quality of human life by enabling people to do more, feel better, and live longer.
Last Close Stock Review
On Monday, October 23, 2017, the stock closed the trading session at $40.62, slightly down 0.54% from its previous closing price of $40.84. A total volume of 6.87 million shares have exchanged hands, which was higher than the 3-month average volume of 3.32 million shares. GlaxoSmithKline's stock price advanced 0.10% in the last one month. Furthermore, since the start of the year, shares of the Company have gained 5.48%. The stock is trading at a PE ratio of 39.13 and has a dividend yield of 4.90%. The stock currently has a market cap of $99.21 billion.
Agenus' share price finished yesterday's trading session at $4.26, sliding 1.62%. A total volume of 12.06 million shares have exchanged hands, which was higher than the 3-month average volume of 1.10 million shares. The Company's stock price rallied 3.90% in the last one month and 15.14% in the past six months. Additionally, the stock gained 3.40% since the start of the year. The stock currently has a market cap of $382.63 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily